清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Neoadjuvant SBRT plus regional nodal irradiation with concurrent capecitabine for patients with resectable pancreatic cancer: Survival analysis of prospective phase 1 trial.

医学 卡培他滨 胰腺癌 放射治疗 阶段(地层学) 癌症 腺癌 新辅助治疗 内科学 外科 肿瘤科 结直肠癌 乳腺癌 古生物学 生物
作者
Mustafa Basree,Jacob S. Witt,Sharon M. Weber,Nataliya V. Uboha,Rebecca M. Minter,Meghan G. Lubner,Daniel E. Abbott,Dustin A. Deming,Noelle K. LoConte,Syed Nabeel Zafar,Monica Patel,Sam Joseph Lubner,Jeremy D. Kratz,Mark A. Ritter,Pranshu Mohindra,M. Bassetti
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:42 (3_suppl): 652-652
标识
DOI:10.1200/jco.2024.42.3_suppl.652
摘要

652 Background: Radiation may have a role in management of patients with early-stage pancreatic cancer. However, the role of regional nodal irradiation (RNI) is not well defined despite the high frequency of occult nodal disease. The goal of this trial was to evaluate the safety and feasibility of stereotactic body radiation therapy (SBRT) to primary disease with RNI, combined with capecitabine as a neoadjuvant approach for patients with resectable pancreatic cancer. Updated survival analysis will be presented here. Methods: This is a prospective, single institution, phase IA/B dose-escalation trial that enrolled patients with biopsy-proven, resectable, pancreatic adenocarcinoma between 2014 – 2019 (NCT1918644). Patients were enrolled into one of the 3 cohorts with escalating dose levels. Neoadjuvant SBRT to the primary tumor was delivered in 5 fractions of 5, 6, or 7 Gy with concomitant capecitabine. All patients received RNI 5 Gy x 5 fractions. Our initial report found no dose-limiting toxicities (Witt et al IJROBP 2020). Clinicopathologic features were summarized using descriptive statistics. Kaplan-Meier curves were employed for survival analysis. Results: Seventeen patients were enrolled on the protocol with sixteen evaluable (94.1%). Thirteen (76.5%) patients proceeded to surgery. Median follow up was 31.1 months (2.0 – 73.2). Among the evaluable patients, 63% were male, median age at diagnosis was 73 years (63 – 84), pre-treatment CA 19-9 149.5 U/mL (2.0 – 19358.0). The majority of patients had cT2-3 (94%) and cN0 (87.5%) disease. In patients who underwent resection, median time from radiation to surgery was 19.7 days (14.8 – 42.4), with median of 18 lymph nodes removed (11 – 27). Pathologically involved nodes were present in 69.2% of patients with a median of 2 nodes (1 – 10). Five patients (31.3%) received neoadjuvant chemotherapy, and ten (62.5%) received adjuvant chemotherapy. At the time of data cutoff, median overall survival was 31.1 months (2.3 – 73.6), and median locoregional control and distant metastasis free survivals were 32.8 months (4.0 – 59.5) and 15.3 months (0.4 – 73.6), respectively. No further radiation related toxicities were noted since the prior report. Conclusions: Neoadjuvant chemoradiation with SBRT and capecitabine to primary disease with RNI is feasible and provided a promising signal of durable local control in our study, despite high rates of pathological nodal involvement. Further investigation of this strategy is warranted in a larger cohort of patients. Clinical trial information: NCT1918644 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
淡然藏花完成签到 ,获得积分10
4秒前
苏su完成签到 ,获得积分10
16秒前
完美梨愁完成签到 ,获得积分10
18秒前
苗条的小蜜蜂完成签到 ,获得积分10
18秒前
爱撒娇的紫菜完成签到,获得积分10
29秒前
zhao完成签到,获得积分10
31秒前
37秒前
42秒前
Kristina完成签到,获得积分10
44秒前
雪山飞龙完成签到,获得积分10
47秒前
小乙猪完成签到 ,获得积分0
55秒前
赘婿应助科研通管家采纳,获得10
1分钟前
charliechen完成签到 ,获得积分10
1分钟前
有魅力荟完成签到,获得积分20
1分钟前
keyan完成签到 ,获得积分10
1分钟前
Connie完成签到,获得积分10
2分钟前
zhilianghui0807完成签到 ,获得积分10
2分钟前
QiaoHL完成签到 ,获得积分10
2分钟前
2分钟前
Yolo完成签到 ,获得积分10
2分钟前
方琼燕完成签到 ,获得积分10
2分钟前
蔡勇强完成签到 ,获得积分10
2分钟前
秋夜临完成签到,获得积分10
2分钟前
樊樊樊梵情完成签到 ,获得积分10
2分钟前
冰封火种发布了新的文献求助30
2分钟前
亚麻帅帅完成签到 ,获得积分10
2分钟前
Axel完成签到,获得积分10
2分钟前
无幻完成签到 ,获得积分10
3分钟前
poki完成签到 ,获得积分10
3分钟前
wendydqw完成签到 ,获得积分10
3分钟前
不与仙同完成签到 ,获得积分10
3分钟前
Shrimp完成签到 ,获得积分10
4分钟前
专注寻菱完成签到,获得积分10
4分钟前
courage完成签到 ,获得积分10
4分钟前
熊二完成签到,获得积分10
4分钟前
魏开铭发布了新的文献求助30
4分钟前
微卫星不稳定完成签到 ,获得积分10
4分钟前
nianshu完成签到 ,获得积分10
4分钟前
vampire完成签到,获得积分10
4分钟前
观妙散人完成签到,获得积分10
4分钟前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Les Mantodea de Guyane Insecta, Polyneoptera 1000
Structural Load Modelling and Combination for Performance and Safety Evaluation 1000
Conference Record, IAS Annual Meeting 1977 820
電気学会論文誌D(産業応用部門誌), 141 巻, 11 号 510
Typology of Conditional Constructions 500
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3571317
求助须知:如何正确求助?哪些是违规求助? 3141926
关于积分的说明 9444838
捐赠科研通 2843331
什么是DOI,文献DOI怎么找? 1562830
邀请新用户注册赠送积分活动 731326
科研通“疑难数据库(出版商)”最低求助积分说明 718524